Home-based Whole Course Multimodal Prehabilitation Based on 5G + Artificial Intelligence Mobile Health

Official record

Identifier

NCT07764523

Recruiting locations

country

China

Interventions studied

mHealth prehabilitation groupERAS group

Lead sponsor

The Affiliated Hospital of Qingdao University

Target enrolment

328 participants

Study type

INTERVENTIONAL

Phase

Not applicable

Status

Not yet recruiting

First posted

Aug 14, 2026

Last updated on the registry

Aug 14, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Aged 18 years or older
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
* Histologically confirmation of gastric or gastroesophageal junction (GEJ) adenocarcinoma. For GEJ carcinomas, eligibility is strictly confined to those presenting with Siewert type III tumors or Siewert type II tumors that do not mandate a concurrent thoracotomy
* Multidisciplinary team (MDT) referral for neoadjuvant chemotherapy prior to gastrectomy
* For female participants of childbearing potential, a negative serum pregnancy test must be confirmed within 7 days prior to the initial administration of neoadjuvant therapy
* Capacity to comprehend and voluntarily sign a written informed consent form
* Ability to use digital technology (e.g., smart phones, wearable devices) independently or with the assistance of family members

Exclusion Criteria:

* Distant metastasis
* Severe cardiac dysfunction (preoperative LVEF \< 30% or NYHA classification IV), severe liver dysfunction (Child-Pugh C grade), severe kidney dysfunction (preoperative CRRT was received), ASA grade IV or above; 6MWD ≤ 250 meters
* Within 6 months before enrollment, the patient had experienced cerebral hemorrhage, cerebral infarction, TIA, or suffered from central nervous system diseases or mental disorders, and was unable to cooperate in completing neoadjuvant therapy and prehabilitation
* Presence of severe systemic infections (e.g., multiple organ dysfunction syndrome \[MODS\]) or active infectious diseases (e.g., tuberculosis)
* Emergency surgery is required due to complications of the tumor (e.g. bleeding, perforation, obstruction)
* Simultaneous tumors or other diseases requiring simultaneous surgery (excluding laparoscopic cholecystectomy)
* Patients who are participating in any other clinical trials (except observational, non-interventional clinical study)

Indexed under

Gastric Cancer